Validated in both intrinsic and acquired trastuzumab-resistant HER2-positive cell lines and cell-derived xenograft models, inhibition of FGFR4 dramatically increased cell and tumor susceptibility to anti-HER2 therapy. Here, ERBB2 is linked to neoplasm.